ATC Group: A10B Blood glucose lowering drugs, excl. insulins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10B in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins

Group A10B contents

Code Title
A10BA Biguanides
A10BB Sulfonamides, urea derivatives
A10BC Sulfonamides (heterocyclic)
A10BD Combinations of oral blood glucose lowering drugs
A10BF Alpha glucosidase inhibitors
A10BG Thiazolidinediones
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BX Other blood glucose lowering drugs, excl. insulins

Active ingredients in A10B

Active Ingredient Description
Acarbose

Acarbose is an alpha-glucosidase inhibitors, used in the treatment of diabetes. Inhibitors of a-glucosidase retard the breakdown of carbohydrates in the food and reduce the increase in blood glucose levels, which occurs after each meal.

Acetohexamide
Albiglutide

Albiglutide is an agonist of the GLP-1 receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.

Alogliptin

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

Bexagliflozin

Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Buformin
Canagliflozin

Canagliflozin is an orally-active inhibitor of SGLT2. The SGLT2 transporter, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG).

Chlorpropamide

Chlorpropamide is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. It appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide lowers blood glucose during long-term administration has not been clearly established.

Dapagliflozin

Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion.

Dulaglutide

Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. In contrast to native GLP-1, dulaglutide is resistant to degradation by DPP-4, and has a large size that slows absorption and reduces renal clearance. Dulaglutide improves glycaemic control through the sustained effects of lowering fasting, pre-meal and postprandial glucose concentrations in patients with type 2 diabetes.

Empagliflozin

Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2). Empagliflozin improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption.

Ertugliflozin

Ertugliflozin helps to lower blood glucose by making the patient pass out glucose in the urine. It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.

Evogliptin

The glucagon-like peptide-1 (GLP-1) is secreted from alimentary canal in response to meal that promotes insulin secretion from pancreas and regulates blood sugar post meal by controlling glucagon secretion. Evogliptin exhibits a hypoglycemic effect by controlling the decomposition of GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4) activity and thereby increasing blood concentration of active form GLP-1.

Exenatide

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways. Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells.

Gemigliptin
Glibenclamide

Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.

Glibornuride
Gliclazide

Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans.

Glimepiride

Glimepiride is an orally active hypoglycaemic substance belonging to the sulphonylurea group. It may be used in non-insulin dependent (type 2) diabetes mellitus. Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.

Glipizide

Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue.

Gliquidone

Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Imeglimin
Ipragliflozin
Linagliptin

Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase 4, EC 3.4.14.5) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide1, glucose-dependent insulinotropic polypeptide). These hormones are rapidly degraded by the enzyme DPP-4. Both incretin hormones are involved in the physiological regulation of glucose homeostasis.

Linagliptin and Empagliflozin

Antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes. Linagliptin is an inhibitor of DPP-4 an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide). Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2.

Liraglutide

Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration.

Lixisenatide

Lixisenatide is a selective GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of hypoglycaemia, the rescue mechanism of glucagon secretion is preserved.

Lobeglitazone
Luseogliflozin

Luseogliflozin lowers plasma glucose by inhibiting the activity of sodium-glucose cotransporter 2 (SGLT2) which is involved in reabsorption of glucose at renal proximal tubules and promoting the excretion of excessive glucose in blood into urine.

Metformin

Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.

Metformin and Alogliptin
Metformin and Canagliflozin

Combination of two oral glucose-lowering medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: canagliflozin, an inhibitor of SGLT2 transporter, and metformin hydrochloride, a member of the biguanide class.

Metformin and Dapagliflozin

Combination fo two anti-hyperglycaemic medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Empagliflozin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), and metformin hydrochloride, a member of the biguanide class.

Metformin and Ertugliflozin

Combination of two anti-hyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and metformin, a member of the biguanide class.

Metformin and Linagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Pioglitazone

Combination of two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class. Thiazolidinediones act primarily by reducing insulin resistance and biguanides act primarily by decreasing endogenous hepatic glucose production.

Metformin and Rosiglitazone

Combination of two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: rosiglitazone, a member of the thiazolidinedione class and metformin, a member of the biguanide class. Thiazolidinediones act primarily by reducing insulin resistance and biguanides act primarily by decreasing endogenous hepatic glucose production.

Metformin and Saxagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: saxagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Sitagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Vildagliptin

Combination of two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: vildagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class.

Miglitol

Miglitol is a reversible inhibitor of intestinal alpha-glucosidases. Under the influence of miglitol, the digestion of complex carbohydrates into absorbable monosaccharides in the small intestine is dosedependently delayed. Administration of miglitol thus leads to reduced postprandial hyperglycaemia and a smoothing effect on fluctuations in the daily blood glucose profile.

Mitiglinide
Nateglinide

Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents. Nateglinide is a rapid, short-acting oral insulin secretagogue. Its effect is dependent on functioning beta cells in the pancreas islets.

Omarigliptin
Phenformin

Phenformin is a biguanide hypoglycemic agent with actions and uses similar to those of metformin. It activates AMP-activated protein kinase (AMPK) and inhibits mTORC1 signaling. Phenformin used for the treatment of diabetes. Phenformin exerts potential anti-neoplastic action.

Pioglitazone

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

Pioglitazone and Alogliptin

Combination of two antihyperglycaemic medicinal products with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and pioglitazone, a member of the thiazolidinedione class.

Pramlintide

Pramlintide is an analog of human amylin. In human studies, pramlintide, acting as an amylin analog, slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake.

Repaglinide

Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets.

Rosiglitazone

Rosiglitazone is a selective agonist at the PPARγ (peroxisomal proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of anti-diabetic agents. It reduces glycaemia by reducing insulin resistance at adipose tissue, skeletal muscle and liver.

Saxagliptin

Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor. Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.

Saxagliptin and Dapagliflozin

Combination of saxagliptin and dapagliflozin with complementary mechanisms of action to improve glycaemic control. Saxagliptin, through the selective inhibition of dipeptidyl peptidase-4 (DPP-4), enhances glucose-mediated insulin secretion (incretin effect). Dapagliflozin, a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), inhibits renal glucose reabsorption independently of insulin. Actions of both medicinal products are regulated by the plasma glucose level.

Semaglutide

Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

Sitagliptin

Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones.

Sitagliptin and Ertugliflozin

Combination of two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor.

Sotagliflozin

Sotagliflozin is an inhibitor of SGLT2 and SGLT1. Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium which may influence several physiological functions such as lowering both pre-and afterload of the heart and downregulating sympathetic activity. Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea. The mechanism for sotagliflozin’s cardiovascular benefits has not been established.

Teneligliptin

Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor. It acts as a competitive reversible inhibitor of DPP-4 and decreases the degradation of incretins, especially GLP-1, thereby improving hyperglycemia by stimulating insulin secretion and suppressing glucagon secretion in a glucose-dependent manner (no or negligible risk of hypoglycemia).

Tirzepatide

Tirzepatide is a long acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, brain, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes. The activity of tirzepatide on the GIP receptor is similar to native GIP hormone. Tirzepatide improves glycaemic control by lowering fasting and postprandial glucose concentrations in patients with type 2 diabetes through several mechanisms.

Tolbutamide

Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.

Trelagliptin
Vildagliptin

Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion by increasing the endogenous levels of these incretin hormones. The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

Voglibose

Related product monographs

Title Information Source Document Type  
ACTOS Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ACTOS Tablet European Medicines Agency (EU) MPI, EU: SmPC
AMARYL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
AMGLIDIA Oral suspension European Medicines Agency (EU) MPI, EU: SmPC
AVANDAMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
AVANDIA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
AVANDIA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
BRENZAVVY Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
BROT Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
BYETTA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
COMPETACT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
DIABETMIN Prolonged release tablet Marketing Authorisation Holder MPI, EU: SmPC
DIABREZIDE Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
DIAFORMIN Film-coated tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
DIAMICRON MR Modified release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
DUFORZIG Tablet Health Products Regulatory Authority (ZA) MPI, Generic
ENYGLID Tablet European Medicines Agency (EU) MPI, EU: SmPC
EPERZAN Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
EUCREAS Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
FORXIGA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
GALVUS MET Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
GALVUS Tablet European Medicines Agency (EU) MPI, EU: SmPC
GLIBESYN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLICLAZIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLITISOL Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLIZOREM Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLUCOBAY 50mg Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLUCOPHAGE Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLUCOPHAGE Tablet / Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GLUCOTROL Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
GLUCOTROL XL Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GLUCOVANCE Film-coated tablet Web Search MPI, EU: SmPC
GLUMETZA Film coated tablet, extended release FDA, National Drug Code (US) MPI, US: SPL/PLR
GLUSTIN Tablet European Medicines Agency (EU) MPI, EU: SmPC
GLYFORMIN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLYXAMBI Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
INCRESYNC Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
INPEFA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
INVOKANA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JALRA Tablet European Medicines Agency (EU) MPI, EU: SmPC
JALRAMET Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
JANUMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JANUVIA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JARDIANCE Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JENTADUETO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
KOMBIGLYZE XR Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
KOMBOGLYZE Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
LAMZARIN Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
LUSEFI Film-coated tablet Web Search MPI, Generic
LYXUMIA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
MEDOCLAZIDE Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
METFORAL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
METFORMIN Oral Solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MINIDIAB Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
MINODIAB Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MOUNJARO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
NESINA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ONGLYZA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
OZEMPIC Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
PIOGLITAZONE ACCORD Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PRANDIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
QTERN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
REPAGLINIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RISTABEN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
RYBELSUS Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
SAGALATIN Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
SAXENDA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SEGLUROMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
SIOFOR Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
STARLIX Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
STEGLATRO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
STEGLUJAN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
SYNJARDY Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TESAVEL Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TRAJENTA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TRULICITY Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
VICTOZA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
VIPDOMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VIPIDIA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VOKANAMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
WEGOVY Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
XIGDUO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYNQUISTA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC